$696.00 – $969.00
Verzenio is an antineoplastic drug.
It is indicated for the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor type 2 (HER2-) advanced or metastatic breast cancer:
– in combination with first-line endocrine therapy with an aromatase inhibitor;
– in combination with fulvestrant, prescribed as first- or second-line endocrine therapy;
– as monotherapy in patients with disease progression after endocrine therapy and one or two lines of previous chemotherapy for metastatic disease.
Active ingredient: abemaciclib
Prescription medicine
| Дозировка | 50 Mg, 100 Mg, 150 Mg |
|---|
